{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:30:39Z","timestamp":1793403039880,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>GLP-1\u2013based medications have rapidly reshaped the landscape of obesity treatment. Semaglutide was approved for obesity treatment in 2021 in the US and 2022 in Europe, sparking global interest, and the GLP-1\/GIP dual-agonist tirzepatide has demonstrated even greater efficacy. However, survey-based data on who uses or considers these medications\u2014particularly across socioeconomic groups, BMI categories, and weight management experiences\u2014remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/methods<\/jats:title>\n                    <jats:p>\n                      A nationally representative online survey of Finnish adults (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091729, of which 1693 were included) was conducted in June 2025 via a market research company using quota sampling. Use and awareness of GLP-1 medications for obesity were measured with a single item listing widely known brands\u2014Ozempic, Wegovy, Zepbound, and Mounjaro\u2014to aid recognition. In regression analyses, current, past, and potential users (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009322) were combined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 3.5% reported current and 2.0% past use, and 13.5% expressed interest in future use. Notably, ~40% of individuals with obesity reported no interest. Bivariate analysis showed that current use was more common among women, those aged 50\u201369, those with household income exceeding \u20ac70,000, individuals with higher BMI, frequent weight loss attempts, experiences of weight-based discrimination, and self-blame. Multivariable analysis showed that current, past, and potential use had strongest associations with BMI \u226530.0\u2009kg\/m\u00b2, repeated or persistent weight loss attempts, experiences of discriminatory treatment due to weight, self-blaming thoughts and hopeful perceptions of GLP-1 medications. Concern about serious health risks was associated with lower likelihood of use or interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1\u2013based medications are gaining recognition, but uptake remains heterogeneous and many individuals with obesity remain uninterested. Concerns about potential health risks persist. Attitudes toward these medications are shaped not only by weight status but also by prior weight management experiences and perceptions. Clinical communication should be sensitive to these factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41366-026-02149-5","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:15:52Z","timestamp":1783440952000},"page":"2137-2147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 medications: use and interest in a representative survey of Finns"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-2636","authenticated-orcid":false,"given":"Piia Tuuli","family":"Jallinoja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8522-1288","authenticated-orcid":false,"given":"Kirsi H.","family":"Pietil\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia W.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2149_CR1","unstructured":"FDA. Wegovy\u2014semaglutide. U.S. Food and Drug Administration, 2021."},{"key":"2149_CR2","unstructured":"EMA. Wegovy\u2014semaglutide. European Medicines Agency, 2022."},{"key":"2149_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384:989\u20131002.","journal-title":"NEJM"},{"key":"2149_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b7 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u201384.","journal-title":"Lancet"},{"key":"2149_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Pfeiffer AF. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diab Obes Metab. 2021;23:5\u201329.","journal-title":"Diab Obes Metab"},{"key":"2149_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. NEJM. 2025;393:26\u201336.","journal-title":"NEJM"},{"key":"2149_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. NEJM. 2025;392:958\u201371.","journal-title":"NEJM"},{"key":"2149_CR8","volume-title":"Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs","author":"J Hari","year":"2024","unstructured":"Hari J Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs. London: Bloomsbury Publishing; 2024."},{"key":"2149_CR9","unstructured":"EMA. Mounjaro. European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro, 2022."},{"key":"2149_CR10","unstructured":"FDA. ZEPBOUND\u00ae (tirzepatide) Injection, for subcutaneous use. U.S. Food and Drug Administration, 2025."},{"key":"2149_CR11","unstructured":"FDA. Mounjaro. U.S. Food and Drag Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf, 2022."},{"key":"2149_CR12","unstructured":"EMA. Saxenda. European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/saxenda, 2025."},{"key":"2149_CR13","unstructured":"EMA. Victoza. European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/victoza, 2009."},{"key":"2149_CR14","unstructured":"Ukhanova, M Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. The American Journal of Managed Care. 2025;1."},{"key":"2149_CR15","unstructured":"Kela. Lihavuusl\u00e4\u00e4kkeit\u00e4 k\u00e4ytt\u00e4\u00e4 jo yli 100 000 suomalaista \u2013 kasvu jatkuu eritt\u00e4in voimakkaana. The Social Insurance Institution of Finland. 2026. https:\/\/tietotarjotin.fi\/uutinen\/1361928\/lihavuuslaakkeita-kayttaa-jo-yli-100-000-suomalaista-kasvu-jatkuu-erittain-voimakkaana?q=semaglutiini. Accessed 3 March 2026."},{"key":"2149_CR16","doi-asserted-by":"crossref","unstructured":"Harjunen, H, Puhakka, A (Re) conceptualizing fatness as a medical and moral issue in the Finnish media discourse on fat and Ozempic in 2022\u20132023. Fat Studies. 2025.","DOI":"10.1080\/21604851.2025.2529706"},{"key":"2149_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/CLEP.S456170","volume":"16","author":"A Mailhac","year":"2024","unstructured":"Mailhac A, Pedersen L, Potteg\u00e5rd A, S\u00f8ndergaard J, Mogensen T, S\u00f8rensen H, et al. Semaglutide (Ozempic\u00ae) use in Denmark 2018 through 2023. Clin Epidemiol. 2024;16:307\u201318.","journal-title":"Clin Epidemiol"},{"key":"2149_CR18","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.7326\/M24-0019","volume":"177","author":"YH Yeo","year":"2024","unstructured":"Yeo YH, Rezaie A, Hsieh TY-J, Hu X, Gaddam S, Ma KS-K, et al. Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis. Ann Intern Med. 2024;177:1289\u201391.","journal-title":"Ann Intern Med"},{"key":"2149_CR19","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1111\/dom.16291","volume":"27","author":"PLD Ruiz","year":"2025","unstructured":"Ruiz PLD, Hindenes LB, Karlstad \u00d8, N\u00f8kleby K, Meyer HE, Mailhac A, et al. Trends in the use of drugs with weight-loss effect: Scandinavian study from 2017 to 2023. Diab Obes Metab. 2025;27:2901\u20135.","journal-title":"Diab Obes Metab"},{"key":"2149_CR20","unstructured":"Reuters. Weight Watchers files for chapter 11 bankruptcy to cut debt. 2025. https:\/\/www.reuters.com\/business\/weightwatchers-plans-file-bankruptcy-protection-2025-05-06\/. Accessed 1 Nov 2025."},{"key":"2149_CR21","unstructured":"FDA. WEGOVY (semaglutide) injection, for subcutaneous use, 2025."},{"key":"2149_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/eat.24109","volume":"57","author":"S Bartel","year":"2024","unstructured":"Bartel S, McElroy SL, Levangie D, Keshen A. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. Int J Eat Disord. 2024;57:286\u201393.","journal-title":"Int J Eat Disord"},{"key":"2149_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100181","volume":"15","author":"D Mozaffarian","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine. Obes Pillars. 2025;15:100181.","journal-title":"Obes Pillars"},{"key":"2149_CR24","volume":"15","author":"MA Algarni","year":"2023","unstructured":"Algarni MA, Algarni AAM, Alqarni WA, Alqassim AY. Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study. Cureus. 2023;15:e42875.","journal-title":"Cureus"},{"key":"2149_CR25","unstructured":"Pew Research Centre. How Americans view weight-loss drugs and their potential impact on obesity in the U.S. www.pewcentre.com, 2024."},{"key":"2149_CR26","unstructured":"KFF. KFF Health Tracking Poll May 2024: The Public\u2019s Use and Views of GLP-1 Drugs. KFF, 2024."},{"key":"2149_CR27","doi-asserted-by":"publisher","first-page":"e002519","DOI":"10.1136\/bmjph-2024-002519","volume":"3","author":"N Auerbach","year":"2025","unstructured":"Auerbach N, Liu VN, Huang D, Clift AK, Al-Ammouri M, El-Osta A. What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional study in the UK. BMC Pub Health. 2025;3:e002519.","journal-title":"BMC Pub Health"},{"key":"2149_CR28","doi-asserted-by":"publisher","first-page":"e0314407","DOI":"10.1371\/journal.pone.0314407","volume":"19","author":"R Abutaima","year":"2024","unstructured":"Abutaima R, Barakat M, Sawan HM, Al Omari SM, Mhaidat NM. Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study. PloS one. 2024;19:e0314407.","journal-title":"PloS one"},{"key":"2149_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bodyim.2025.101890","volume":"53","author":"CH Markey","year":"2025","unstructured":"Markey CH, August KJ, Malik D, Richeson A. Body image and interest in GLP-1 weight loss medications. Body Image. 2025;53:101890.","journal-title":"Body Image"},{"key":"2149_CR30","unstructured":"Tynkkynen L-K, Keskim\u00e4ki I, Karanikolos M, Litvinova Y. Finland: health system summary 2023. European Observatory on Health Systems and Policies, 2023."},{"key":"2149_CR31","unstructured":"Lehtoranta L, Kaartinen N, J\u00e4\u00e4skel\u00e4inen T, M\u00e4ki P, Pietil\u00e4inen K, Sares-J\u00e4ske L, et al. Lihavuus [Obesity]. Finnish Institute for Health and Welfare. 2023. https:\/\/www.thl.fi\/tervesuomi_verkkoraportit\/ilmioraportit_2023\/lihavuus.html. Accessed 16 May 2026."},{"key":"2149_CR32","unstructured":"EurostatOverweight and obesity - BMI statistics. Luxembourg: Publications Office of the European Union; 2025."},{"key":"2149_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1108\/IJHCQA-04-2015-0041","volume":"29","author":"AO Saarinen","year":"2016","unstructured":"Saarinen AO, R\u00e4s\u00e4nen P, Kouvo A. Two dimensions of trust in physicians in OECD-countries. Int H Health Care Qual Assur. 2016;29:48\u201361.","journal-title":"Int H Health Care Qual Assur"},{"key":"2149_CR34","unstructured":"Wellcome Global Monitor. How does the world feel about science and health. London: Wellcome Trust; 2018. https:\/\/wellcome.org\/reports\/wellcome-global-monitor\/2018."},{"key":"2149_CR35","unstructured":"Tieteen tiedotus. Tiedebarometri [Science Barometer]. Helsinki: Tieteen tiedotus; 2024. https:\/\/www.tieteentiedotus.fi\/files\/Tiedebarometri_2024.pdf"},{"key":"2149_CR36","unstructured":"Statistics Finland. Population structure and educational structure of population. https:\/\/stat.fi\/en\/statistics, 2025."},{"key":"2149_CR37","unstructured":"THL. Lihavien osuus - Terve Suomi 2024 [The prevalence of obesity - Healthy Finland Survey 2024]. Finnish Institute For Health and Welfare. 2025. https:\/\/www.thl.fi\/tervesuomi_verkkoraportit\/kyselyosuus_2024\/ath_obesity_bmi30.html. Accessed 16 May 2026."},{"key":"2149_CR38","unstructured":"THL. Quality report: The adult population\u2019s well-being and health \u2013 Healthy Finland survey. Finnish Institute for Health and Welfare. 2025. https:\/\/thl.fi\/en\/data-and-statistics\/data-quality\/quality-reports-on-statistics\/quality-report-the-adult-population-s-well-being-and-health-healthy-finland-survey#quality-report-the-adult-populations-well-being-and-health-healthy-finland-survey. Accessed 16 May 2026."},{"key":"2149_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/asj\/sjad211","volume":"44","author":"SH Han","year":"2024","unstructured":"Han SH, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A, et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a google trends analysis. Aesthet Sur J. 2024;44:60\u20137.","journal-title":"Aesthet Sur J"},{"key":"2149_CR40","unstructured":"Brumberg JJ Fasting girls: The emergence of anorexia nervosa as a modern disease. New York: Vintage Books; 1988."},{"key":"2149_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4324\/9781003140665-5","volume-title":"The contemporary reader of gender and fat studies","author":"H Harjunen","year":"2023","unstructured":"Harjunen H. Gendered fat bodies as neoliberal bodies. In: The contemporary reader of gender and fat studies. London & New York: Routledge; 2023. p. 30\u201340."},{"key":"2149_CR42","unstructured":"Eurostat. Key figures on Europe. 2025 edition. Luxembourg: Publications Office of the European Union; 2025."}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02149-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02149-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02149-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:01:06Z","timestamp":1793401266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02149-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2149"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02149-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8016813\/v1","asserted-by":"object"}]},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jallinoja and Chang declare no competing financial or other interests. Pietil\u00e4inen declares the following: Lectures\/Honoraria: AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Lundbeck, Johnson & Johnson, MSD, Novo Nordisk, Orion, UCB. Advisory Board: Boehringer Ingelheim, Eli Lilly & Company, IKEA, Novo Nordisk, Takeda, Vivus. Grants: Novo Nordisk Foundation, grant numbers NNF10OC1013354, NNF17OC0027232, NNF20OC0060547, NNF24OC0091683, NNF25SA0103783.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}